Extracorporeal photopheresis for the treatment of Crohn's disease

Sharyle Fowler, Jennifer Jones, Peter R Hull, Subrata Ghosh

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Small, open-label studies show promising results for ECP in the treatment of steroid-dependent and medically-refractory Crohn's disease. However, proper randomized, sham-controlled trials have not yet been performed. Based on the proposed mechanism of action of ECP, induction of a tolerogenic T cell response, ECP should be assessed in patients with early inflammatory disease rather than those who have progressed to fibrotic or stricturing disease. Randomized, sham-controlled trials need to be performed before ECP can be incorporated into standard clinical practice for the treatment of Crohn's disease.

Original languageEnglish
Pages (from-to)183-186
Number of pages4
JournalTransfusion and Apheresis Science
Issue number2
Early online date15 Feb 2015
Publication statusPublished - Apr 2015


  • Blood Component Removal
  • Clinical Trials as Topic
  • Crohn Disease
  • Humans
  • Immunosuppressive Agents
  • Inflammation
  • Photopheresis
  • Research Design
  • Steroids
  • T-Lymphocytes
  • Treatment Outcome
  • Journal Article
  • Review


Dive into the research topics of 'Extracorporeal photopheresis for the treatment of Crohn's disease'. Together they form a unique fingerprint.

Cite this